Jacobs Bruce N. 4
4 · Kymera Therapeutics, Inc. · Filed Apr 1, 2025
Insider Transaction Report
Form 4
Jacobs Bruce N.
Chief Financial Officer
Transactions
- Exercise/Conversion
Common Stock
2025-03-31$2.08/sh+25,000$52,000→ 226,886 total - Exercise/Conversion
Stock Option (Right to Buy)
2025-03-31−25,000→ 69,899 totalExercise: $2.08Exp: 2029-08-28→ Common Stock (25,000 underlying)
Footnotes (1)
- [F1]Twenty-five percent (25%) of the shares underlying this stock option vested on July 1, 2020 and the remaining shares vested in equal monthly installments over the remaining thirty-six (36) months, subject to the reporting person's continued employment through each vesting date.